London, United Kingdom — Plexus Ventures is pleased to announce the conclusion of a successful divestment assignment for Novartis Consumer Health (Switzerland), for which Plexus Ventures acted as exclusive external advisor. Novartis recently sold the rights to...

London, United Kingdom — Plexus Ventures announces the successful completion of a divestment managed on behalf of Labormed, the largest independent pharmaceutical in Romania. The company divested a package of Rx and OTC products to Recordati of Italy.

London, United Kingdom — Plexus Ventures is pleased to announce the successful completion of a divestment project. Plexus provided transaction services to AstraZeneca UK Limited in the divesture of three of the company's antimalarial brands — PaludrineTM, AvloclorTM...

Los Angeles, California — The Plexus Ventures team is saddened to announce that Klaus Welzel PhD., Senior Consultant - Frankfurt, passed away on July 23, 2012. Klaus is survived by his wife Renate, three adult children, and two grandchildren. The funeral was held on...

Los Angeles, California — Plexus Ventures is pleased to announce the successful completion of its most recent divestment project. Plexus provided professional services to Novartis Consumer Health in the divestiture of an OTC product having European sales to a...

Plexus Ventures Concludes Product Divestment Assignment Los Angeles, California — Plexus Ventures is pleased to announce the successful completion of its most recent divestment project. Plexus provided professional services to Novartis Consumer Health in the...

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Glenmark Pharmaceuticals. Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This transaction is an ideal...